Natco Pharma appeal gets rejected in US court

16 Nov 2022 , 01:42 PM

Ibrutinib tablet is the generic equivalent of Imbruvica tablet. Natco and its co-development & marketing partner, Alvogen Pine Brook, USA, are assessing their option on the way forward, said the company. Ibrutinib is in a class of medications called kinase inhibitors. It helps to stop the spread of cancer cells. Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It markets and distributes products in over 40 countries. On a consolidated basis, Natco Pharma reported 12.7% decline in net profit to Rs 320.40 crore despite of 14.6% increase in net sales to Rs 432.10 crore in Q2 FY23 over Q2 FY22. Powered by Capital Market – Live News